---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126317"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:01:06.138399+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Metagenomi nominates MGX-001 DC for hemophilia A; reports $274.6M cash; Q3 expenses down

## Summary
- Nominated MGX-001 as first development candidate for hemophilia A; IND-enabling activities initiated, IND filing on track for 2026.
- Cash, cash equivalents and marketable securities $274.6M at Sept 30, 2024; cash runway expected into 2027.
- R&D expenses $26.3M in Q3 2024 (vs $26.8M Q3 2023); G&A $7.6M (vs $7.9M).
- Ionis collaboration: all four wave 1 programs in lead optimization; one to two DC nominations expected in 2025.
- Novel ABE platform targets >95% of genome base pairs; SMART platform enables single-AAV delivery for neuromuscular.

## SEC filing metadata
- accession: 0000950170-24-126317
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017024126317/0000950170-24-126317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017024126317/mgx-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126317
- JSON: https://secwatch.observer/filing/0000950170-24-126317.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.